Go back

Industry in uproar over Democrats’ drug pricing move

Drug companies claim move to lower costs for US patients is already hampering pharmaceutical R&D

The Biden administration’s introduction of centralised price negotiations for prescription drugs will negatively affect pharmaceutical research as well as patients, the drug industry has warned.

On 29 August, the US Department of Health and Human Services announced the first 10 prescription drugs for which prices will be negotiated this year and next by the HHS secretary.

This article is only available to Research Professional News subscribers or Pivot-RP users.

If you are a Research Professional News subscriber you can log in and view the article via this link

Pivot-RP users can log in and view the article via this link.